Samsung Biologics secures over ₩5 trillion in annual CMO orders

Samsung Biologics said it has reached a historic milestone, surpassing 5 trillion won ($3.5 billion) in cumulative annual contract manufacturing organization (CMO) orders for the first time since its founding, driven by a series of high-profile deals with global pharmaceutical companies.

Samsung Biologics announced via two disclosures that it had signed two new CMO agreements with a European pharmaceutical company on Wednesday. The contracts are worth a combined 930.4 billion won ($668.39 million), with the first valued at 752.4 billion won and the second at 178 billion won.

Together, these agreements represent approximately 30 percent of the company’s total order volume for 2022 (3.5 trillion won). While the client and product details remain confidential due to a non-disclosure agreement, the contracts are valid through Dec. 31, 2031.

Samsung Biologic stressed that this deal marks a significant achievement for the company as it has inked 11 contracts this year alone, totaling 5.3 trillion won—1.5 times the order volume recorded in 2022—in just 11 months.

Samsung Biologics has demonstrated its robust CDMO capabilities this year, securing high-value contracts across the U.S., Asia, and Europe.

Notably, in July, the company signed a 1.46 trillion won deal with a U.S.-based pharmaceutical company, followed by a record-breaking 1.7 trillion won contract with an Asian firm in October.

Samsung Biologics now counts 17 of the world’s top 20 pharmaceutical companies among its clients, reflecting its strong reputation for manufacturing capacity, quality standards, and proven track record.

The company’s cumulative order volume has exceeded $16.1 billion, further solidifying its dominance in the CDMO sector.